Nerio Therapeutics
acquired by Boehringer IngelheimLa Jolla, US · Founded 2019 · Delaware corporation · 1 known investors
Phosphatase-focused immunotherapy drug discovery company; acquired by Boehringer-Ingelheim for up to $1.3B in 2024.
Biotech
Founders & leadership
SH
Stefan HellerDirector
SJ
Sanford J. Madigan, Ph.D.Executive Officer, Director
JL
Jay Lichter, Ph.D.Director
TR
Tighe ReardonExecutive Officer, Director
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$3.5MraisedOct 2021 · 5 investors · BiotechnologyRule 506(b)
▶$3.5MraisedOct 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sanford J. Madigan, Ph.D.Executive Officer, Director
- Jay Lichter, Ph.D.Director
- Tighe ReardonExecutive Officer, Director
- Stefan HellerDirector
- Offering amount
- $10M
- Amount sold
- $3.5M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3MraisedJul 2020 · 5 investors · BiotechnologyRule 506(b)
▶$3MraisedJul 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tighe ReardonExecutive Officer, Director
- Stefan HellerDirector
- Sanford J. Madigan, Ph.D.Executive Officer, Director
- Jay Lichter, Ph.D.Director
- Offering amount
- $5.8M
- Amount sold
- $3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.